The Rosacea Forum: Papulopustular,
Telangiectatic, and Phymatous Subtypes

A new study from the San Gallicano Dermatologic Institute in Rome shows that a topical treatment based on silymarin/methylsulfonilmethane (S-MSM) can be effective in treating stage I-III rosacea patients. Drs. Berardesca et al used the topical medications on 46 patients over 30 days in a double-blind, placebo controlled study. Instrumental evaluations were done after 10 and 20 days to measure itching, stinging, erythema, papules, as well as hydration and erythema.

The study reports:

“A statistically significant improvement was observed in many clinical and instrumental parameters investigated (P < 0.001). In particular, improvement of skin redness, papules, itching, hydration, and skin color occurred.

Conclusions: The combination of silymarin and S-MSM can be useful in managing symptoms and condition of rosacea skin, especially in the rosacea subtype 1 erythemato-telangiectatic phase. The action can be considered multicentric and multiphase because of the direct modulating action on cytokines and angiokines normally involved and up-regulated in the case of such skin condition.”

The further research into both topical and laser/light based treatments shows a great deal of promise for sufferers of rosacea.

This entry was posted on Monday, February 11th, 2008 at 4:34 pm and is filed under Lasers and IPL, Topicals and Creams. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.